BMC Cancer (Mar 2020)

Guy’s cancer cohort – real world evidence for cancer pathways

  • C. Moss,
  • A. Haire,
  • F. Cahill,
  • D. Enting,
  • S. Hughes,
  • D. Smith,
  • E. Sawyer,
  • A. Davies,
  • J. Zylstra,
  • K. Haire,
  • A. Rigg,
  • M. Van Hemelrijck

DOI
https://doi.org/10.1186/s12885-020-6667-0
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background The burden of disease due to cancer remains substantial. Since the value of real-world evidence has also been recognised by regulatory agencies, we established a Research Ethics Committee (REC) approved research database for cancer patients (Reference: 18/NW/0297). Construction and content Guy’s Cancer Cohort introduces the concept of opt-out consent processes for research in a subset of oncology patients diagnosed and treated at a large NHS Trust in the UK. From April 2016 until March 2017, 1388 eligible patients visited Guy’s and St Thomas’ NHS Foundation Trust (GSTT) for breast cancer management. For urological cancers this number was 1757 and for lung cancer 677. The Cohort consists of a large repository of routinely collected clinical data recorded both retrospectively and prospectively. The database contains detailed clinical information collected at various timepoints across the treatment pathway inclusive of diagnostic data, and data on disease progression, recurrence and survival. Conclusions Guy’s Cancer Cohort provides a valuable infrastructure to answer a wide variety of research questions of a clinical, mechanistic, and supportive care nature. Clinical research using this database will result in improved patient safety and experience. Guy’s Cancer Cohort promotes collaborative research and will accept applications for the release of anonymised datasets for research purposes.

Keywords